- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO , Aug. 5, 2020 /PRNewswire/ -- Arena Pharmaceuticals,
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer
- Ongoing clinical programs remain on track with data readouts expected between 2020-21 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1bn as of March 31, 2020 SAN DIEGO , May 7, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , April 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer session
- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2019 financial results and provide a corporate update on Wednesday, February 26, 2020 , after the close of the U.S. financial markets.
- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel syndrome (IBS) - Multiple first- or best-in-class drug candidates, skilled leadership team and
SAN DIEGO , July 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live